249 related articles for article (PubMed ID: 36310169)
1. SIRPα antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment.
Kong D; Yang Z; Li G; Wu Q; Gu Z; Wan D; Zhang Q; Zhang X; Cheng S; Liu B; Zhang K; Zhang W
BMC Med; 2022 Oct; 20(1):376. PubMed ID: 36310169
[TBL] [Abstract][Full Text] [Related]
2. Single-cell transcriptomics of peripheral blood reveals anti-tumor systemic immunity induced by oncolytic virotherapy.
Wu Q; Hu X; Zhang X; Kong D; Yang Z; Li G; Gu Z; Zhang Q; Wan D; Cheng S; Liu B; Zhang K; Zhang W
Theranostics; 2022; 12(17):7371-7389. PubMed ID: 36438484
[No Abstract] [Full Text] [Related]
3. An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma.
Xu B; Tian L; Chen J; Wang J; Ma R; Dong W; Li A; Zhang J; Antonio Chiocca E; Kaur B; Feng M; Caligiuri MA; Yu J
Nat Commun; 2021 Oct; 12(1):5908. PubMed ID: 34625564
[TBL] [Abstract][Full Text] [Related]
4. The Multifaceted Role of Macrophages in Oncolytic Virotherapy.
Hofman L; Lawler SE; Lamfers MLM
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452439
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial.
Zhang B; Huang J; Tang J; Hu S; Luo S; Luo Z; Zhou F; Tan S; Ying J; Chang Q; Zhang R; Geng C; Wu D; Gu X; Liu B
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837053
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Safety Evaluation of Oncolytic Herpes Simplex Virus Type 2.
Wang Y; Zhou X; Wu Z; Hu H; Jin J; Hu Y; Dong Y; Zou J; Mao Z; Shi X; Huo Y; Lyu J; Fang Z; Zhang W; Zhu Y; Li B; Liu B
Hum Gene Ther; 2019 May; 30(5):651-660. PubMed ID: 30499341
[TBL] [Abstract][Full Text] [Related]
7. Integrating oncolytic viruses in combination cancer immunotherapy.
Bommareddy PK; Shettigar M; Kaufman HL
Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
[TBL] [Abstract][Full Text] [Related]
8. A novel oncolytic virus induces a regional cytokine storm and safely eliminates malignant ascites of colon cancer.
Dong S; Liu B; Hu S; Guo F; Zhong Y; Cai Q; Zhang S; Qian Y; Wang J; Zhou F
Cancer Med; 2022 Nov; 11(22):4297-4309. PubMed ID: 35510373
[TBL] [Abstract][Full Text] [Related]
9. OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment.
Liu S; Li F; Ma Q; Du M; Wang H; Zhu Y; Deng L; Gao W; Wang C; Liu Y; Zhao Z; Liu H; Wang R; Tian Y; Hu M; Wan Y; Lu W; Zhang M; Zhao M; Cao Y; Zhang H; Wang W; Wang H; Wang Y
Theranostics; 2023; 13(12):4016-4029. PubMed ID: 37554264
[No Abstract] [Full Text] [Related]
10. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
11. Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.
De Silva N; Atkins H; Kirn DH; Bell JC; Breitbach CJ
Cytokine Growth Factor Rev; 2010; 21(2-3):135-41. PubMed ID: 20338801
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
Crupi MJF; Taha Z; Janssen TJA; Petryk J; Boulton S; Alluqmani N; Jirovec A; Kassas O; Khan ST; Vallati S; Lee E; Huang BZ; Huh M; Pikor L; He X; Marius R; Austin B; Duong J; Pelin A; Neault S; Azad T; Breitbach CJ; Stojdl DF; Burgess MF; McComb S; Auer R; Diallo JS; Ilkow CS; Bell JC
Front Immunol; 2022; 13():1029269. PubMed ID: 36405739
[TBL] [Abstract][Full Text] [Related]
13. Design and application of oncolytic viruses for cancer immunotherapy.
Ylösmäki E; Cerullo V
Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424
[TBL] [Abstract][Full Text] [Related]
14. Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma.
Zhang L; Wang W; Wang R; Zhang N; Shang H; Bi Y; Chen D; Zhang C; Li L; Yin J; Zhang H; Cao Y
Mol Ther; 2021 Feb; 29(2):744-761. PubMed ID: 33130310
[TBL] [Abstract][Full Text] [Related]
15. OH2 oncolytic virus: A novel approach to glioblastoma intervention through direct targeting of tumor cells and augmentation of anti-tumor immune responses.
Zheng Y; Wang X; Ji Q; Fang A; Song L; Xu X; Lin Y; Peng Y; Yu J; Xie L; Chen F; Li X; Zhu S; Zhang B; Zhou L; Yu C; Wang Y; Wang L; Hu H; Zhang Z; Liu B; Wu Z; Li W
Cancer Lett; 2024 May; 589():216834. PubMed ID: 38537773
[TBL] [Abstract][Full Text] [Related]
16. Combining oncolytic virotherapy and tumour vaccination.
Bridle BW; Hanson S; Lichty BD
Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
[TBL] [Abstract][Full Text] [Related]
17. Optimal timing of PD-1 blockade in combination with oncolytic virus therapy.
Nguyen HM; Bommareddy PK; Silk AW; Saha D
Semin Cancer Biol; 2022 Nov; 86(Pt 3):971-980. PubMed ID: 34033895
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy.
Xie D; Tian Y; Hu D; Wang Y; Yang Y; Zhou B; Zhang R; Ren Z; Liu M; Xu J; Dong C; Zhao B; Yang L
Signal Transduct Target Ther; 2023 Nov; 8(1):436. PubMed ID: 38016957
[TBL] [Abstract][Full Text] [Related]
19. Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages.
Shen Z; Liu X; Fan G; Na J; Liu Q; Lin F; Zhang Z; Zhong L
J Transl Med; 2023 Nov; 21(1):842. PubMed ID: 37993941
[TBL] [Abstract][Full Text] [Related]
20. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
